NDAORALTABLETPriority Review
Approved
Apr 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRECATOR (ethionamide) is an oral small-molecule antibiotic approved in 1965 for the treatment of tuberculosis, particularly drug-resistant and multi-drug-resistant (MDR-TB) strains. It is a second-line agent used in combination therapy when first-line TB drugs are ineffective or contraindicated. The drug works by inhibiting mycobacterial cell wall synthesis.
LOE Approaching
As a decades-old product approaching loss of exclusivity with low linked job count, this brand likely operates with a lean team focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
Started Mar 2026
64 enrolled
Tuberculosis Meningitis
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
Started Jun 2022
30 enrolled
Tuberculosis, Pulmonary
Career Relevance
TRECATOR presents minimal career growth opportunity due to zero linked job openings, mature product stage, and approaching loss of exclusivity. Roles available are primarily operational or compliance-focused rather than commercial expansion or strategic development positions.
Product Manager (Legacy)
Worked on TRECATOR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.